SG3 Management’s Fate Therapeutics FATE Stock Holding History

SG3 Management’s Portfolio FATE Stock Details FATE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-60,000	Closed	-$2.33M	–	539
2022 Q1	$2.33M	Buy	60,000 +20,000	+50%	+$774K	0.07%	272
2021 Q4	$2.34M	Buy	40,000 +15,000	+60%	+$850K	0.05%	307
2021 Q3	$1.48M	Buy	+25,000	New	+$1.96M	0.04%	370
2021 Q2	–	Sell	-30,000	Closed	-$2.47M	–	1115
2021 Q1	$2.47M	Buy	+30,000	New	+$2.87M	0.06%	349

Other funds holding FATE

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

SG3 Management's FATE Position: Q2 2022 in Review

SG3 Management sold out of Fate Therapeutics (FATE) in Q2 2022, closing a stake of 30,000 shares — an estimated $1.16M sold.

SG3 Management first reported a position in FATE in Q4 2020 and held it in 3 quarters. The position peaked at $1.98M in Q1 2021. 233 funds tracked by Wall St. Rank hold FATE as of Q2 2022.

SG3 Management reported no remaining Fate Therapeutics position as of Q2 2022 after selling out during the quarter.
SG3 Management sold 30,000 Fate Therapeutics shares in Q2 2022, an estimated $1.16M.
SG3 Management first reported a position in Fate Therapeutics in Q4 2020 and held it in 3 quarters.
SG3 Management's Fate Therapeutics position peaked at $1.98M in Q1 2021.
233 funds tracked by Wall St. Rank held Fate Therapeutics as of Q2 2022.

Based on SG3 Management's 13F filing for Q2 2022, filed 15 Aug 2022.